Related Experiment Video
Updated: Jul 26, 2025
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
563
[Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients with Advanced Non-small Cell
Yibo Wang1, Xinjuan Wang1, Lin Cheng1
1Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|June 14, 2023
Summary
Thyroid function abnormality (TFA) is a common side effect of immunotherapy in advanced non-small cell lung cancer (NSCLC). Patients experiencing TFA may have better treatment outcomes, including longer progression-free survival.
Area of Science:
- Oncology
- Endocrinology
- Immunotherapy
Context:
- Thyroid function abnormality (TFA) is a frequent adverse event in advanced non-small cell lung cancer (NSCLC) patients undergoing immunotherapy.
- Risk factors for TFA and its correlation with treatment efficacy remain unclear.
Purpose:
- To investigate the risk factors associated with TFA in advanced NSCLC patients treated with immunotherapy.
- To determine the relationship between TFA and the efficacy of immunotherapy in this patient population.
Summary:
- Retrospective analysis of 200 advanced NSCLC patients revealed TFA in 43.0%.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS), pleural effusion, and lactic dehydrogenase (LDH) were identified as risk factors for TFA.
- Patients with TFA demonstrated significantly longer progression-free survival (PFS), higher objective response rates (ORR), and disease control rates (DCR) compared to those with normal thyroid function.
- ECOG PS, LDH, cytokeratin 19 fragment (CYFRA21-1), and TFA were significant prognostic factors.
Impact:
- Identifies key risk factors for TFA in advanced NSCLC patients receiving immunotherapy.
- Suggests TFA may serve as a predictive biomarker for improved immunotherapy response and prognosis.
- Highlights the potential for better therapeutic outcomes in NSCLC patients who develop TFA during immunotherapy.
